Janssen and the European Foundation for the Study of Diabetes Announce Award Recipient Who Will Bring Further Understanding of the Role of the Kidney in Diabetes and Research Fellowships Awarded to Four Emerging Researchers
The European Foundation for the Study of Diabetes (EFSD) today announced that Dr Ivonne Loeffler, University Hospital, Jena, Germany is the recipient of this year’s award for the ‘EFSD/Janssen Programme for the Study of the Role of the Kidney in Diabetes’. Dr Loeffler will be looking into the role of collagen type Vlll in epithelial-mesenchymal transition in diabetic nephropathy, advancing knowledge in a therapy area which affects an estimated 329 million people worldwide.
The award programme, initiated in 2010, is a joint partnership between EFSD and Janssen and offers joint funding of up to €300,000 per year. Within this up to €100,000 is available for basic research projects and €200,000 for clinical research projects, with a view to improving disease management.
Also announced today, four leading young researchers have been awarded EFSD/Janssen Research Fellowships in conjunction with the European Association for the Study of Diabetes (EASD) Rising Star Symposium in recognition of their innovative work in diabetes research. Amélie Bonnefond, Lille Pasteur Institute, France; Josefine Beulens, Utrecht University, The Netherlands; Laura Herrero, University of Barcelona, Spain and Henrike Sell, German Diabetes Center, Duesseldorf, Germany will present an overview of their past and current research activities at the EASD Rising Star Symposium and will each receive further funding of €30,000 to continue their work through the EFSD/Janssen Research Fellowships.
“Diabetes is a global concern and the social and economic impact of this disease is increasing as the incidence and prevalence of diabetes continues to grow. Through our partnership with Janssen, we are pleased to support further research into the role of the kidney in diabetes and also to recognise and support the emerging researchers who have valuable contributions to make to expand our knowledge and understanding of diabetes” said Prof Andrew Boulton, President EFSD.
“Janssen is committed to working alongside the diabetes community and is proud to sponsor the EFSD/Janssen Programme for the Study of the Role of the Kidney in Diabetes and the EFSD/Janssen Research Fellowships during the Rising Stars Symposium at the EASD Annual Meeting. Programmes such as these stimulate and accelerate vital research that could contribute to improving management of the disease and patient care” commented Brian Woodfall, Vice President Janssen EMEA Medical Affairs.
-- ENDS --
Notes to editors
For more information about the EFSD/Janssen research programme visit: http://www.europeandiabetesfoundation.org/
About EFSD
The European Foundation for the Study of Diabetes (EFSD) was created by the European Association for the Study of Diabetes (EASD) to provide funding initiatives in all areas of diabetes research. The aims of EFSD are to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge and to facilitate its application.
About Janssen
The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology, immunology, neuroscience, infectious disease, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world.
More information can be found at www.janssen-emea.com
Contact:
Media contacts:
Brigitte Byl
Janssen, Public Affairs &
Communications EMEA
Phone: +32 (0)14 60 7172
or
Katy Gray
Reynolds-MacKenzie
Phone:
+44 (0)207 861 2806 / +44 (0)779 470 0151
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Geoswift Launches Visa Direct to Enhance Cross-Border Payment Offers in Over 30 Countries30.4.2025 03:00:00 CEST | Press release
Geoswift announced today the integration of Visa Direct with Geoswift's cross-border payments platform. Visa Direct facilitates payouts to more than 140 countries and territories. The integration will enable payouts in 32 countries and territories, across 13 currencies, covering major markets in Asia Pacific, North America, Europe and Middle East, with plans for more in the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423288249/en/ Bryan Ma, SVP, Head of Geoswift Global Payments, and Swapnil Mhasde, Head of Visa Direct Commercialization and Solutions, Asia Pacific, celebrating the launch in Singapore. Geoswift is a leading provider of cross-border payment services and solutions globally. With over two decades of innovation, it has become a trusted name in B2B, education, eCommerce, remittance, and travel payment use cases. Raymond Qu, Group CEO of Geoswift, stated, "At Geoswift, our vision has always been to del
Logitech Announces Q4 and Full Fiscal Year 2025 Results29.4.2025 22:03:00 CEST | Press release
A Year of Broad-Based Sales Growth, Expanded Market Share and Increased Profitability, Driven by Strategic Priorities SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2025 ended March 31, 2025. For Fiscal Year 2025: Sales were $4.55 billion, up 6 percent in US dollars and 7 percent in constant currency, compared to the prior year. GAAP operating income was $655 million, up 11 percent compared to the prior year. Non-GAAP operating income was $775 million, up 11 percent compared to the prior year. GAAP earnings per share (EPS) was $4.13, up 7 percent compared to the prior year. Non-GAAP EPS was $4.84, up 14 percent compared to the prior year. Cash flow from operations was $843 million. The year-ending cash balance was $1.5 billion. The Company returned $797 million of cash to shareholders through its annual dividend payment and share repurchases.
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene29.4.2025 21:32:00 CEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC’s (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding. On November 1, 2023, BeiGene filed a PGR petition with the USPTO challenging the validity of certain claims of the ‘803 patent, in response to a patent infringement lawsuit Pharmacyclics brought against BeiGene concerning BRUKINSA® (zanubrutinib). On May 1, 2024, the USPTO granted BeiGene’s petition to institute the PGR. The USPTO’s Final Written Decision is appealable by Pharmacyclics. Commenting on the ruling, BeiGene General Counsel Chan Lee said: “We are pleased that the USPTO invalidated all challenged claims of the ‘803 patent. Today’s decision reinforces our belief th
One out of Three Secure Civil IDs Delivered Each Year Is Powered by Thales29.4.2025 16:50:00 CEST | Press release
In a world where identity fraud represents a critical vulnerability for citizens and societies, Thales is leading the transformation of civil identity into a secure and citizen-first service. Through its advanced Civil Identity Suite, Thales enables governments worldwide to protect their citizens, ensuring protection at every stage of the identity journey and for the entire identity chain. Supporting more than 300 national identity programmes and having enrolled over 500 million people, Thales is uniquely positioned to deliver secure and responsible identity solutions. Each year, Thales powers one in three smart civil IDs (official electronic documents) issued worldwide, highlighting the company’s key role in shaping the future of identities and helping governments and citizens transition smoothly to digital. With its Civil Identity Suite, Thalesenables the issuance and management of both physical and digital identities, as well as all means of enrolling citizens and enabling seamless
Solving Border Control Staffing Challenges: Regula Launches an Ecosystem for Remote Document Examination29.4.2025 15:00:00 CEST | Press release
Regula, a global developer of forensic devices and identity verification solutions, introduces an innovative solution designed to transform document examination processes, particularly in border control operations. Based on high-resolution photospectral scanners from the Regula 88XX product line, it enables highly accurate and reliable remote document authentication, effectively addressing the pressing issue of staffing shortages in border security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250429852027/en/ High-resolution photospectral scanner Regula 8880 for remote document verification (Photo: Regula) Traditionally, document authenticity experts needed to be physically present at each checkpoint. However, this requirement has become increasingly challenging due to current staffing constraints. For example, a recent European Commission report highlights gaps in the availability of certain specialized experts, notably
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom